Post by Hot Christian Stocks on May 12, 2012 11:37:18 GMT -5
About Viral Genetics, Inc.
Viral Genetics, Inc. is a biotechnology company researching new treatments and methods of detection for HIV/AIDS, Lyme Disease, staph and strep, cancer and certain other autoimmune and infectious diseases. Two approaches based on patent rights licensed from the University of Colorado and University of Vermont form the basis of our research: Targeted Peptides Therapies (TPT) and Metabolic Disruption Technology (MDT). TPTs are custom-designed protein fragment that work to modify certain immune system reactions that we believe cause or worsen some diseases. The TPT compounds we are studying represent in some sense the second generation of our earlier thymus nuclear protein or “TNP” therapy. MDT encompasses a way to change how some types of cells use fat and sugar/carbohydrates for energy. By manipulating metabolic processes, we believe we can cause some harmful cells – including drug-resistant cancer cells – to die. The same MDT approach has also recently been discovered to have potential in encouraging the production of oils from algae and other plants. As a result of this, we established a subsidiary called VG Energy to develop these applications.
Our management team and advisors include two Nobel Laureates, Dr. Luc Montagnier and Dr. Baruch Blumberg, leading researchers, business and intellectual property veterans and drug development experts.
Contact Info
2290 Huntington Drive
Suite 100
San Marino, CA 91108
United States
Phone: 626-334-5310
Fax: 626-334-5324
www.viralgenetics.com
Our Team: Haig Keledjian, CEO, President
Chief Executive Officer and President
Mr. Keledjian has been instrumental in guiding the growth and development of Viral Genetics, Inc., having acted as its Chairman, Chief Executive Officer and President since its 1995 founding. He has overseen the completion of VGV-1's six human clinical trials, including the recently completed Phase III trial in South Africa, the creation of Viral Genetics' global intellectual property portfolio and the financing of Viral Genetics.
Mr. Keledjian is a California attorney. Prior to joining Viral Genetics, he practiced tax and estate law
Technology: Overview
As a discovery company, we are focused on finding and developing treatments and methods of detection for HIV/AIDS, Lyme Disease, staph and strep infection, cancer and certain other autoimmune and infectious diseases. Two approaches developed by Dr. M. Karen Newell-Rogers form the basis of our research: Targeted Peptides Therapies (TPT) and Metabolic Disruption Technology (MDT). All of our compounds are in the late preclinical stage and we are now preparing to submit pre-IND documents to the FDA for clinical trials in the US. An investigator’s IND for our glioblastoma therapy using an MDT approach is planned for January 2011.
TPTs are custom-designed protein fragments that work to modify certain immune system reactions that we believe cause or worsen some inflammatory diseases. The TPT compounds we are studying represent in some sense the second generation of our earlier TNP therapy. MDT encompasses a way to change how some types of cells use fat, amino acids and sugars or carbohydrates for energy. By manipulating metabolic processes, we can cause some harmful cells – including drug-resistant cancer cells – to die. The same MDT approach has also recently been discovered to have potential in encouraging the production and storage of biofuels from algae and other plants.